Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma

Resolvin E1 (RvE1; 5S, 12R, 18R-trihydroxyeicosapentaenoic acid) is an anti-inflammatory lipid mediator derived from the omega-3 fatty acid eicosapentaenoic acid (EPA). It has been recently shown that RvE1 is involved in the resolution of inflammation. However, it is not known whether RvE1 is involv...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2008-03, Vol.367 (2), p.509-515
Main Authors: Aoki, Haruka, Hisada, Takeshi, Ishizuka, Tamotsu, Utsugi, Mitsuyoshi, Kawata, Tadayoshi, Shimizu, Yasuo, Okajima, Fumikazu, Dobashi, Kunio, Mori, Masatomo
Format: Article
Language:English
Subjects:
Airway hyperresponsiveness
Airway inflammation
Animals
Asthma - drug therapy
Asthma - immunology
Asthma - pathology
Bronchial asthma
Bronchial Hyperreactivity - drug therapy
Bronchial Hyperreactivity - immunology
Bronchial Hyperreactivity - pathology
Disease Models, Animal
Dose-Response Relationship, Drug
Eicosapentaenoic Acid - administration & dosage
Eicosapentaenoic Acid - analogs & derivatives
Female
Lipid mediator
Lung - drug effects
Lung - immunology
Lung - pathology
Mice
Mice, Inbred BALB C
Pneumonia - drug therapy
Pneumonia - immunology
Pneumonia - pathology
Resolvin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Resolvin E1 (RvE1; 5S, 12R, 18R-trihydroxyeicosapentaenoic acid) is an anti-inflammatory lipid mediator derived from the omega-3 fatty acid eicosapentaenoic acid (EPA). It has been recently shown that RvE1 is involved in the resolution of inflammation. However, it is not known whether RvE1 is involved in the resolution of asthmatic inflammation. To investigate the anti-inflammatory effect of RvE1 in asthma, a murine model of asthma was studied. After RvE1 was administered to mice intraperitoneally, there were decreases in: airway eosinophil and lymphocyte recruitment, specific Th2 cytokine, IL-13, ovalbumin-specific IgE, and airway hyperresponsiveness (AHR) to inhaled methacholine. Moreover, RvE1-treated mice had significantly lower mucus scores compared to vehicle-treated mice based on the number of goblet cells stained with periodic acid-schiff (PAS). These findings provide evidence that RvE1 is a pivotal counterregulatory signal in allergic inflammation and offer novel multi-pronged therapeutic approaches for human asthma.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2008.01.012